Table 4 Treatment exposure
Maintenance (n = 18) | Treatment (n = 33) | Total (n = 51) | |
|---|---|---|---|
Initial dose 600 mg twice daily | 18 (100%) | 30 (91%) | 48 (94%) |
Treatment duration, months | 7.5 (1.1–15.5) | 2.4 (0.2–16.7) | 3.3 (0.2–16.7) |
Treatment duration* | |||
0–12 months | 12 (80%) | 30 (97%) | 42 (91%) |
12–24 months | 3 (20%) | 1 (3%) | 4 (9%) |
Dose interruptions † | 10 (56%) | 20 (63%) | 30 (60%) |
0 | 8 (44%) | 12 (38%) | 20 (40%) |
1 | 8 (44%) | 13 (41%) | 21 (42%) |
2 | 0 | 7 (22%) | 7 (14%) |
≥ 3 | 2 (11%) | 0 | 2 (4%) |
Dose reductions † | 11 (61%) | 14 (44%) | 25 (50%) |
0 | 7 (39%) | 18 (56%) | 25 (50%) |
1 | 5 (28%) | 11 (34%) | 16 (32%) |
2 | 5 (28%) | 3 (9.4) | 8 (16%) |
3 | 1 (6%) | 0 | 1 (2%) |
Reason for discontinuation | |||
Progression | 13 (72%) | 25 (76%) | 38 (75%) |
Toxicity | 1 (6%) | 4 (12%) | 5 (10%) |
Other‡ | 1 (6%) | 2 (6%) | 3 (6%) |
On treatment | 3 (17%) | 2 (6%) | 5 (10%) |